BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sartorius said, based on its assessment of future market development, the company expects its addressable markets to grow at a rate of approximately 7 to 9 percent per year over the medium term. Against this backdrop, Sartorius introduced a new medium-term ambition for the period from 2027 onwards. Management expects the company to consistently outgrow its addressable markets by around 100 to 200 basis points per year leading to an organic sales revenue growth in constant currencies of 8 to 11 percent per year at group level. Also, underlying EBITDA margin at group level is supposed to grow by approximately 50 to 75 basis points per year.
The company aims to strengthen its core business by reinforcing its leadership positions in mission-critical applications in process intensification, single-use technologies and cell analytics. Sartorius plans to further develop select emerging businesses, including advanced therapy solutions, advanced cell models, process analytical technologies and analytical characterization and quality control platforms.
At last close, Sartorius shares were trading at 209.00 euros, down 0.33%.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
